Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms

Leukemia and Lymphoma

Volumn 53, Issue 1, 2012, Pages 123-129

  Skov, Vibe ^a   Larsen, Thomas Stauffer ^b   Thomassen, Mads ^a   Riley, Caroline Hasselbalch ^c   Jensen, Morten K ^c   Bjerrum, Ole Weis ^c   Kruse, Torben A ^a   Hasselbalch, Hans Carl ^c  

^a Department of Clinical Genetics ^*  (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Gene expression; Histone deacetylases; Philadelphia negative chronic myeloproliferative neoplasms

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN; MALE; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASES; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; REPRESSOR PROTEINS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84855464431     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.597905     Document Type: Article

References (75)

1. W ard HP, Block MH. Th e natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 1971;50:357-420.
2. R eilly JT. Idiopathic myelofi brosis: pathogenesis, natural history and management. Blood Rev 1997;11:233-242. (Pubitemid 28045207)
3. H asselbalch HC. Idiopathic myelofi brosis. Am J Hematol 1990;34:291-300.
4. Teff eri A. Th e chronic myeloproliferative disorders. Semin Hematol 1999;36(Suppl. 2):3-8.
5. Teff eri A. Myelofi brosis with myeloid metaplasia N Engl J Med 2000;342:1255-1265.
6. Spivak JL. Th e chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004;41(Suppl. 3):1-5. (Pubitemid 38657103)
7. F ruchtman SM. Treatment paradigms in the management of chronic myeloproliferative disorders. Semin Hematol 2004;41(Suppl. 3):18-22. (Pubitemid 38657107)
8. Elliot MA, Teff eri A. Th rombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275-290. (Pubitemid 40216149)
9. M esa RA, Barosi G, Cervantes F, et al. Myelofi brosis with myeloid metaplasia: disease overview and non-transplant treatment options. Best Pract Res Clin Haematol 2006;19:495-517. (Pubitemid 43863142)
10. J ones PA, Baylin SB. Th e epigenomics of cancer. Cell 2007;128: 683-692. (Pubitemid 46273572)
11. S trahl BD, Allis CD. Th e language of covalent histone modifi cations. Nature 2000;403:421-445.
12. G regory PD, Wagner K, Hortz W. Histone acetylation and chromatine remodeling. Exp Cell Res 2001;265:195-202.
13. R oth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001;70:81-120. (Pubitemid 32662206)
14. G ray SG, Ekstrom TJ. Th e human histone deacetylase family. Exp Cell Res 2001;262:75-83. (Pubitemid 32980246)
15. Th iagalingam S, Cheng KH, Lee HJ, et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 2003;983:84-100. (Pubitemid 36399322)
16. de Ruijter AJM, van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-749. (Pubitemid 36399066)
17. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-784. (Pubitemid 44348499)
18. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-5467.
19. Blander G, Guarente L. Th e Sir2 family of protein deacetylases. Annu Rev Biochem 2004;73:417-435. (Pubitemid 39050375)
20. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7:437-443. (Pubitemid 32298546)
21. Schafer S, Jung M. Chromatin modifi cations as targets for new anticancer drugs. Arch Pharm (Weinheim) 2005;338:347-357.
22. Bi G, Jiang G. Th e molecular mechanism of HDAC inhibitors in anticancer eff ects. Cell Mol Immunol 2006;3:285-290.
23. Gu W, Roeder RG. Activation of p53 sequence-specifi c DNA binding by acetylation of the p53 C-terminal domain. Cell 1997;90:595-606. (Pubitemid 27357952)
24. Martinez-Balbas MA, Bauer UM, Nielsen SJ, et al. Regulation of E2F1 activity by acetylation. EMBO J 2000;19:662-671. (Pubitemid 30093739)
25. P atel JH, Du Y, Ard PG, et al. Th e c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol 2004;24:10826-10834. (Pubitemid 39603138)
26. Chen L, Fischle W, Verdin E, et al. Duration of nuclear NFkappaB action regulated by reversible acetylation. Science 2001;293: 1653-1657. (Pubitemid 32807844)
27. Jeong JW, Bae MK, Ahn MY, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002;111:709-720.
28. Cohen HY, Lavu S, Bitterman KJ, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004;13:627-638. (Pubitemid 38368121)
29. Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005;18:601-607. (Pubitemid 40726236)
30. Y uan ZL, Guan YJ, Chatterjee D, et al. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005;307:269-273. (Pubitemid 40116244)
31. Z hang Y, Li N, Caron C, et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 2003;22: 1168-1179. (Pubitemid 36313600)
32. M inucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51. (Pubitemid 43054973)
33. Wang JC, Chen C, Dumlao T, et al. Enhanced histone deacetytase enzyme activity in primary myelofi brosis. Leuk Lymphoma 2008;49: 2321-2327.
34. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150: 446-455.
35. Hasselbalch HC, McMullin M; COSMYD Working Group and Nordic Myeloproliferative Study Group. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. EudraCT No. 2007-005306-49. Clinical trials identifi er: NCT00866762.
36. I rizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-264.
37. Smyth GK. Linear models and empirical Bayes methods for assessing diff erential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3: Article 3.
38. B enjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
39. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50.
40. Nakagawa M, Oda Y, Eguchi T, et al. Expression profi le of class I histone deacetylases in human cancer tissues. Oncol Rep 2007;18: 769-774.
41. Osada H, Tatematsu Y, Saito H, et al. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004;112:26-32. (Pubitemid 39249488)
42. I shihama K, Yamakawa M, Semba S, et al. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J Clin Pathol 2007;60: 1205-1210. (Pubitemid 350084539)
43. Z hu P, Martin E, Mengwasser J, et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5:455-463. (Pubitemid 38610247)
44. M arquard L, Poulsen CB, Gjerdum LM, et al. Histone deacetylase 1,2,6 and acetylated histone H4 in B-and T-cell lymphomas. Histopathology 2009;54:688-698.
45. O ' C onnor OA, Heaney MI, Schwartz I, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxyamic acid in patients with advanced haematological malignancies. J Clin Oncol 2006;24:166-173.
46. H uang BH, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1 / WAF1 expression, independent of histone deacetylase 1. Cell Death Diff er 2005;12:395-404. (Pubitemid 40520691)
47. H rzenjak A, Moinfar F, Kremser ML, et al. Valproate inhibition of histone deacetylase 2 aff ects diff erentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Th er 2006;5:2203-2210. (Pubitemid 44530456)
48. W eichert W, Roske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98:604-610. (Pubitemid 351214528)
49. W eichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008;9:139-148.
50. W eichert W, Roske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specifi c role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008;14;1669-1677. (Pubitemid 351469450)
51. Krusche CA, Wulfi ng P, Kersting C, et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005;90:15-23. (Pubitemid 40486997)
52. M arquard L, Gjerdrum LM, Christensen IJ, et al. Prognostic signifi cance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008;53:267-277.
53. Z hang Z, Yamashita H, Toyama T, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004;10:6962-6968. (Pubitemid 39383047)
54. S aji S, Kawakami M, Hayashi S, et al. Signifi cance of HDAC6 regulation via estrogen signalling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005;24: 4531-4539. (Pubitemid 41032616)
55. B radbury CA, Khanim FL, Hayden R, et al. Histone deacetylases in acute leukemia show a distinct pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005;19:1751-1759. (Pubitemid 41486152)
56. K ato H, Tamamizu-Kato S, Shibasaki F. Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem 2004;279:41966-41974. (Pubitemid 39313647)
57. B akin RE, Jung MO. Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis. J Biol Chem 2004;279:51218-51225. (Pubitemid 40017865)
58. H ideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumour activity in multiple myeloma. Proc Natl Acad Sci USA 2005;102: 8567-8572. (Pubitemid 40862776)
59. Fiskus W, Rao R, Fernandez P, et al. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood 2008;112: 2896-2905.
60. H aberland M, Montgomery RL, Olson EN. Th e many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2008;10:32-42.
61. M atsuyama A, Shimazu T, Sumida Y, et al. In vivo destabilization of dynamic microtubules by HDAC6 mediated deacetylation. EMBO J 2002;21:6820-6831. (Pubitemid 36014554)
62. B oyalt C, Zhang Y, Fritah S, et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 2007;21:2172-2181. (Pubitemid 47360839)
63. Zhang Y, Kwon S, Yamaguchi T, et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008;28:1688-1701.
64. Zhang Z, Yamashita H, Toyama T, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004;10:6962-6968. (Pubitemid 39383047)
65. Lee YS, Lim KH, Guo X, et al. Th e cytoplasmic deacetylase HDAC6 is required for effi cient oncogenic tumourigenesis. Cancer Res 2008;68:7561-7569.
66. Zhou X, Marks PA, Rifkind RA, et al. Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci USA 2001;98: 10572-10577. (Pubitemid 32878662)
67. Petrie K, Guidez F, Howell L, et al. Th e histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem 2003;278: 16059-16072. (Pubitemid 36799727)
68. Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet 2003;19:286-293. (Pubitemid 36507011)
69. Kristinsson SY, Landgren O, Samuelsson J, et al. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010;95:1216-1220.
70. V illagra A, Cheng F, Wang HW, et al. Th e histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009;10:92-100.
71. S imonsson M, Heldin CH, Ericsson J, et al. Th e balance between acetylation and deacetylation controls Smad7 stability. J Biol Chem 2005;280:21797-21803. (Pubitemid 40827829)
72. Y uan ZL, Guan YJ, Chatterjee D, et al. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005;307:269-273. (Pubitemid 40116244)
73. Han S, Lu J, Zhang Y, et al. HDAC inhibitors TSA and sodium butyrate enhanced the human IL-5 expression by altering histone acetylation status at its promoter region. Immunol Lett 2007;108: 143-150. (Pubitemid 46198957)
74. L i B, Greene MI. FOXP3 actively represses transcription by recruiting the HAT/HDAC complex. Cell Cycle 2007;6:1432-1436.
75. Maltepe E, Krampitz GW, Okazaki KM, et al. Hypoxia-inducible factor-dependent histone deacetylase activity determines stem cell fate in the placenta. Development 2005;132:3393-3403. (Pubitemid 41246115)